Company Overview and News

 
Amara Raja in tech tie-up with Johnson Controls

2018-10-03 thehindubusinessline
V Rishi Kumar Expanding on their 20-year partnership, Amara Raja Batteries Ltd and Johnson Controls, Inc of the US have signed a collaboration agreement to bring new technologies to India.
500008 ARJQY AMARAJABAT

 
Amara Raja Batteries Limited - Clarification

2018-10-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500008 ARJQY AMARAJABAT

 
Amara Raja Batteries Limited - Trading Window

2018-10-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500008 ARJQY AMARAJABAT

 
Company news: Amara Raja Batteries

2018-09-27 thehindubusinessline
Amara Raja Batteries has entered into an agreement with Johnson Controls Technology Company (JC), US, for acquiring the license for manufacturing advanced stamped grid plate-making technology. The company has also entered into a technology collaboration agreement with JC, which will enable it to manufacture advanced lead acid batteries. Shares of Amara Raja slipped 2.72 per cent at ₹761.15 on the BSE.
500008 ARJQY AMARAJABAT

 
Amara Raja Batteries Limited - Updates

2018-09-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500008 ARJQY AMARAJABAT

 
Amara Raja Batteries Limited - Updates

2018-09-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500008 ARJQY AMARAJABAT

 
Intellect Design, Tata Steel, Alembic Pharma top gainers among BSE Group A stocks

2018-09-12 moneycontrol
The Indian stock market traded higher on Wednesday afternoon with the Nifty50 up 78 points while the Sensex higher by 267 points at 37,680.
ABB 500008 500119 532504 RENUKA ARJQY AMARAJABAT 533104 500470 TTST TATASTEEL 532670 TATLY 500002 NAVINFLUOR ABBDY GLOBUSSPR DHAMPURSUG

4
Amara Raja’s lithium-ion plant eyes $300 billion EV market

2018-09-06 livemint
Mumbai: Amara Raja Batteries Ltd, India’s second-biggest traditional battery maker by value, will build a lithium-ion assembly plant as it seeks to grab a slice of the market for electric vehicle power packs that is set to grow to $300 billion by 2030. The battery maker is in the process of building a 100 megawatt-hour assembly plant in the southern state of Andhra Pradesh and the company is working closely with the Indian Institute of Technology in Chennai, CEO S.
HYUO 500008 AKLD HYUD ARJQY AMARAJABAT 7269 500477 HYUP 500570 TATAMOTORS AKLS ASHOKLEY TTM

 
Amara Raja Batteries Limited - Updates

2018-08-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500008 ARJQY AMARAJABAT

 
Amara Raja Batteries Limited - Updates

2018-08-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500008 ARJQY AMARAJABAT

 
Amara Raja Batteries Q1 net profit up 13%

2018-08-12 moneycontrol
Amara Raja Batteries has posted 13.19 percent jump in its net profit at Rs 113.03 crore during the first quarter of the current fiscal on strong sales. Its net profit was Rs 99.85 crore in the April-June quarter of last fiscal, the company said in a regulatory filing.
500008 ARJQY AMARAJABAT

 
Amara Raja Batteries Limited - Financial Result Updates

2018-08-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500008 ARJQY AMARAJABAT

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...